Eli Lilly and Company announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials. The first-ever facility of its kind, combining research and manufacturing in a single location, the Medicine Foundry will be located in Indiana’s LEAP Research and Innovation District in Lebanon, Indiana, and will expand the company’s investment there to more than $13 billion. “As we accelerate our work to discover new medicines for the toughest diseases, we’re continuing to invest in state-of-the-art infrastructure to support our growing pipeline,” said David A. Ricks, Lilly’s chair and CEO. “In addition to supplying high-quality medicine for our clinical studies, this new complex will further strengthen our process development and scale up our manufacturing capabilities to speed delivery of next-generation medicines to patients around the world.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly thrives as weight-loss drugs boom, closer to $1T valuation, FT says
- CVS to cut jobs, PepsiCo acquires Siete Foods: Morning Buzz
- Eli Lilly wants to study wider use for weight-loss drugs, FT reports
- Quanterix announces commercialization of p-Tau 217 test kit
- Nektar assumed with a Buy at BTIG